Streptococcus pneumoniae or pneumococcus is a bacterium that can become pathogenic and cause respiratory infections (pneumonia, bronchitis, pleurisy) or ENT infections (ear infections, sinusitis, mastoiditis) that can turn into meningitis. Since some strains can be resistant to antibiotics, special surveillance is in place, both in France and abroad. 

Launched in 2012 at the instigation of the European Centre for Disease Control (ECDC), the SpIDNet network (Streptococcus pneumoniae Invasive Disease Network) is a European network to evaluate the impact and effectiveness of the two main vaccine groups currently on the market: conjugate pneumococcal vaccines (PCVs), which currently cover 10 or 13 serotypes (or strains of bacteria), and polysaccharide vaccines such as the 23-valent vaccine (PPV23). 

From 2012 to 2018, 15 partner institutions from 10 EU Member States coordinated by Epiconcept participated in the first phase, dedicated to the evaluation of pneumococcal vaccines. 

From 2015 to 2018, SpIDNet was complemented by the I-MOVE + pneumococcus network funded by the European Commission's Horizon 2020 programme.  

For more information:

Project funded by: